Diagnosis and Treatment of Parkinson’s Disease — State of the Art

1. Front Matter

   Pages i-vii

   PDF

2. Post mortem studies in Parkinson’s disease — is it possible to detect brain areas for specific symptoms?

   • K. A. Jellinger

   Pages 1-29

3. Pathogenesis and preclinical course of Parkinson’s disease

   • P. Foley, P. Riederer

   Pages 31-74

4. Clinical efficacy of budipine in Parkinson’s disease

   • H. Przuntek, T. Müller

   Pages 75-82

5. Multiple mechanisms of action: the pharmacological profile of budipine

   • M. Eltze

   Pages 83-105

6. Parkinson’s disease: one disease entity or many?

   • Amos D. Korczyn

   Pages 107-111

7. Parkinson’s disease — a multifactorial neurodegenerative disorder

   • Olaf Riess, R. Krüger

   Pages 113-125

8. Mechanism and consequences of nerve cell death in Parkinson’s disease

   • Etienne C. Hirsch

   Pages 127-137

9. Functional imaging of Parkinson’s disease: is it possible to detect brain areas for specific symptoms?

   • David J. Brooks

   Pages 139-153

10. Multiple system atrophy

    • W. H. Oertel, O. Bandmann

    Pages 155-164

11. Tremorlytic activity of budipine in Parkinson’s disease

    • Sybille Spieker, S. Breit, T. Klockgether, J. Dichgans

    Pages 165-172

12. Current management of motor fluctuations in patients with advanced Parkinson’s disease treated chronically with levodopa

    • Eldad Melamed, J. Zoldan, R. Galili-Mosberg, I. Ziv, R. Djaldetti

    Pages 173-183

13. Differentiation of dopamine agonists and their role in the treatment of Parkinson’s disease

    • Donald B. Calne

    Pages 185-192

14. Free radical scavengers: chemical concepts and clinical relevance

    • Michael Gassen, M. B. H. Youdim

    Pages 193-210

15. Differential diagnosis of tremor

    • Günther Deuschl

    Pages 211-220

Expert clinicians and basic scientists with a special interest in Parkinson’s disease review the current state of science and clinical therapeutics of the disease. Therefore these articles represent an authorative review of the current state of knowledge regarding preclinical course and symptomatology, subtypes with their impact on the pathology, genetic alterations, novel mechanisms of neuronal cell death, diagnostic tools and old and novel therapeutic approaches with respect to neuroprotection and neuroregeneration in Parkinson’s disease. Particular emphasis has been placed on a novel antiparkinsonian drug called budipine with various modes of action also influencing altered non dopaminergic systems in Parkinson’s disease. It is evident, that many questions on the cause, course and treatment of Parkinson’s disease are still unanswered and therefore the ideal way to treat a parkinsonian patient remains to be defined.

• Budipin
• Budipine
• Neurogeneration
• Neuronaler Zelltod
• Neuroprotektion
• neuronal cell death
• neuroprotection
• neuroregeneration
• preclinical course
• vorklinischer Verlauf
• brain
• cell
• diagnosis
• differential diagnosis
• dopamine
• multiple system atrophy
• Parkinson
• pathogenesis
• pathology
• pharmacology
• research
• treatment
• tremor
• Zelltod

• Department of Neurology, St. Josef Hospital Ruhr University Bochum, Federal Republic of Germany

  H. Przuntek, T. Müller

Policies and ethics